Arvinas (ARVN) Income from Continuing Operations (2017 - 2026)
Arvinas (ARVN) posted quarterly Income from Continuing Operations of 57600000.0 for Q1 2026, down 169.48% year-over-year from 82900000.0 in Q1 2025, and up 14.54% quarter-over-quarter from 67400000.0 in Q4 2025.
Powered by 
Analysis
Arvinas (ARVN) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Arvinas' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 57600000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 169.48% year-over-year to 57600000.0; the TTM figure through Mar 2026 stood at 221300000.0 (down 374.89% YoY), while the FY2025 annual figure was 80800000.0, up 59.38% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 57600000.0, up from 67400000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 82900000.0 in Q1 2025, with the low at 154800000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 63300000.0 (2022), against an average of 57300000.0.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations surged 219.45% in 2025, then plunged 169.48% in 2026.
- Arvinas' Income from Continuing Operations stood at 80100000.0 in 2022, then tumbled by 93.26% to 154800000.0 in 2023, then soared by 70.87% to 45100000.0 in 2024, then sank by 49.45% to 67400000.0 in 2025, then gained by 14.54% to 57600000.0 in 2026.
- Business Quant data shows ARVN's Income from Continuing Operations at 57600000.0 in Q1 2026, 67400000.0 in Q4 2025, and 35100000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Arvinas | 609.77 Mn | 41.87 Mn | - | 169.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 169.40 Mn |
| Mar 31, 2026 | -57.60 Mn |
| Dec 31, 2025 | -67.40 Mn |
| Sep 30, 2025 | -35.10 Mn |
| Jun 30, 2025 | -61.20 Mn |
| Mar 31, 2025 | 82.90 Mn |
| Dec 31, 2024 | -45.10 Mn |
| Sep 30, 2024 | -49.20 Mn |
| Jun 30, 2024 | -35.20 Mn |
| Mar 31, 2024 | -69.40 Mn |
| Dec 31, 2023 | -154.80 Mn |
| Sep 30, 2023 | -63.90 Mn |
| Jun 30, 2023 | -65.30 Mn |
| Mar 31, 2023 | -80.80 Mn |
| Dec 31, 2022 | -80.10 Mn |
| Sep 30, 2022 | -63.30 Mn |
| Jun 30, 2022 | -67.50 Mn |
| Mar 31, 2022 | -61.10 Mn |
| Dec 31, 2021 | -46.10 Mn |
| Sep 30, 2021 | -46.80 Mn |